Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis

Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir

(2016) José L. Casado et al.   AIDS

Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV

(2016) Sanjiv M. Baxi et al.   AIDS

Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV

(2016) Evelyn Hsieh et al.   AIDS

Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients

(2015) Lisa Hamzah et al.   AIDS

Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation

(2015) Edgar Turner Overton et al.   ANNALS OF INTERNAL MEDICINE

Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial

(2015) Kathleen Mulligan et al.   CLINICAL INFECTIOUS DISEASES

Fibroblast growth factor 23: associations with antiretroviral therapy in patients co-infected with HIV and hepatitis C

(2015) J Young et al.   HIV MEDICINE

The PTH-Vitamin D-FGF23 axis

(2015) Jenny E. Blau et al.   REVIEWS IN ENDOCRINE & METABOLIC DISORDERS

Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

(2015) Amanda Mocroft et al.   PLOS MEDICINE

Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis

(2014) Marc M. Solomon et al.   AIDS

Pubertal Timing, Bone Acquisition, and Risk of Fracture Throughout Life

(2014) Jean-Philippe Bonjour et al.   ENDOCRINE REVIEWS

Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study

(2014) Robert M Grant et al.   LANCET INFECTIOUS DISEASES

Common clinical conditions – age, low BMI, ritonavir use, mild renal impairment – affect tenofovir pharmacokinetics in a large cohort of HIV-infected women

(2013) Sanjiv M. Baxi et al.   AIDS

Association of Higher Plasma Vitamin D Binding Protein and Lower Free Calcitriol Levels with Tenofovir Disoproxil Fumarate Use and Plasma and Intracellular Tenofovir Pharmacokinetics: Cause of a Functional Vitamin D Deficiency?

(2013) Peter L. Havens et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study

(2013) Graeme J Moyle et al.   ANTIVIRAL THERAPY

Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC–MS/MS

(2013) Jia-Hua Zheng et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Tenofovir, Emtricitabine, and Tenofovir Diphosphate in Dried Blood Spots for Determining Recent and Cumulative Drug Exposure

(2012) Jose R. Castillo-Mancilla et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Vitamin D3 Decreases Parathyroid Hormone in HIV-Infected Youth Being Treated With Tenofovir: A Randomized, Placebo-Controlled Trial

(2012) P. L. Havens et al.   CLINICAL INFECTIOUS DISEASES

Treatment of Calcium and Vitamin D Deficiency in HIV-Positive Men on Tenofovir-Containing Antiretrovial Therapy

(2012) Anneke Bech et al.   HIV CLINICAL TRIALS

Calcium Deficiency Reduces Circulating Levels of FGF23

(2012) M. E. Rodriguez-Ortiz et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Tenofovir Treatment Duration Predicts Proteinuria in a Multiethnic United States Cohort of Children and Adolescents With Perinatal HIV-1 Infection

(2012) Murli Purswani et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Short Communication: Early Changes in Parathyroid Hormone Concentrations in HIV-Infected Patients Initiating Antiretroviral Therapy with Tenofovir

(2011) Mar Masiá et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Revised Reference Curves for Bone Mineral Content and Areal Bone Mineral Density According to Age and Sex for Black and Non-Black Children: Results of the Bone Mineral Density in Childhood Study

(2011) Babette S. Zemel et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

(2011) Grace A. McComsey et al.   JOURNAL OF INFECTIOUS DISEASES

Systematic Review and Meta‐analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients

(2010) Ryan D. Cooper et al.   CLINICAL INFECTIOUS DISEASES

Bone Disease in HIV Infection: A Practical Review and Recommendations for HIV Care Providers

(2010) Grace A. McComsey et al.   CLINICAL INFECTIOUS DISEASES

Tenofovir-Linked Hyperparathyroidism Is Independently Associated With the Presence of Vitamin D Deficiency

(2010) Melanie M Rosenvinge et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Rapid growth produces transient cortical weakness: A risk factor for metaphyseal fractures during puberty

(2010) Qingju Wang et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Tenofovir-associated renal and bone toxicity

(2009) CLN Woodward et al.   HIV MEDICINE

Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen

(2009) Todd T Brown et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

New Equations to Estimate GFR in Children with CKD

(2009) G. J. Schwartz et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY